Results 181 to 190 of about 38,713 (298)

Prescribing Patterns in Fatal Intoxications Involving Zopiclone and Alprazolam: An Observational Register‐Based Study

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 1, July 2026.
ABSTRACT Background Zopiclone was recently identified as a frequent contributor to fatal drug‐intoxications in Sweden. However, characteristics of misuse and factors associated with prescribed use remain insufficiently described. Alprazolam has a more established misuse profile. Objective The aim of the study was to describe and compare characteristics
Lova Tralla, Sara Gustavsson, Carl Söderberg, Anna K. Jönsson, Fredrik C. Kugelberg   +4 more
wiley   +1 more source

Pharmacy-level barriers to opioid overdose prevention: availability and accessibility of naloxone and buprenorphine-naloxone in high-risk Texas counties. [PDF]

Harm Reduct J
Darouiche KG, Malik MM, Mohr MT, Hagenimana MA, Digbeu BDE, Cunningham KA, Farr NM, Dostal CR.   +7 more
europepmc   +1 more source

A Phase 1, Open‐Label, Randomized Study to Investigate the Pharmacokinetics and Safety of Multiple Doses of Intranasal Naloxone in Healthy Participants

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT This was a Phase 1, open label, randomized, crossover study to evaluate the safety and pharmacokinetics of multiple doses of intranasal naloxone (NCT05377255). Twenty‐four healthy participants were enrolled at a single site in the US to one of two sequences.
David Cassie, Bob Warnock, Faisal Akhtar, Duncan McCloskey, David Wyatt   +4 more
wiley   +1 more source

A comparison of opioid overdose risk behaviors by race and ethnicity among overdose survivors in Boston, MA, and San Francisco, CA. [PDF]

Harm Reduct J
Reed GE, McMahan VM, Chang YG, Johnson NL, Walley AY, Coffin PO, Harris MTH.   +6 more
europepmc   +1 more source

Health, Social and Recidivism Outcomes Among People Who Have Been Incarcerated in New South Wales, Australia: Study Protocol and Cohort Profile for the Prison Outcomes STudy (POST)

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction We have been funded to examine post‐incarceration health and social outcomes for all people incarcerated in New South Wales, Australia, 2000–2022; assess treatment and services for drug dependence and serious mental illness; and project the impact of expanding intervention coverage. We will use a linked cohort, the Prison Outcomes
Louisa Degenhardt, Michael Farrell, Michael Doyle, Jack Stone, Chrianna Bharat, Matt Hickman, Marianne Martinello, Don Weatherburn, Kimberlie Dean, Joe Coyte, Christel Macdonald, Mary Ellen Harrod, Luke Grant, Gloria Larman, Peter Vickerman, Colette McGrath, Peter Thompson, Alison Churchill, Greg Dore, Thomas Santo Jr   +19 more
wiley   +1 more source

Cost-effectiveness of community-based interventions for reducing opioid overdose and non-overdose deaths: simulation modeling of HEALing Communities Study. [PDF]

Lancet Reg Health Am
Chhatwal J, Sahinkoc M, Chen Q, Dowd W, Xiao J, Zarkin GA, Aldridge A, Barocas JA, Cerdá M, Fareed N, Frazier LA, Hyder A, Keyes KM, Knott CE, LaRochelle M, Linas BP, Oga E, Roberts SM, Samet JH, Schackman BR, Seiber EE, Starbird LE, Villani J, Knudsen AB, Barbosa C.   +24 more
europepmc   +1 more source

Prevalence and Correlates of Reporting a Gabapentin Prescription for Pain Among People Who Use Opioids: A Longitudinal Community‐Recruited Study

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Gabapentin is widely prescribed off‐label to treat pain. However, there are concerns about the proliferation of medical and non‐medical use, and the potential increased risk of overdose death associated with concurrent opioid use.
Evelyne Marie Piret, Heather Palis, Alexis Crabtree, JinCheol Choi, Kora DeBeck, Kanna Hayashi, Michael R. Law, M.‐J. Milloy   +7 more
wiley   +1 more source

Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era. [PDF]

Addict Behav
Chambers LC, Hallowell BD, Zullo AR, Rodriguez M, Khan MA, Berk J, Gaither R, Daly M, Wightman RS, Beaudoin FL.   +9 more
europepmc   +1 more source

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD).
Katie Lyman, JinCheol Choi, Didier Jutras‐Aswad, Bernard L. E. Foll, Sukhpreet Klaire, M. Eugenia Socias   +5 more
wiley   +1 more source

Clinical factors linked to xylazine exposure in emergency department patients with illicit opioid overdose. [PDF]

Addiction
Love JS, Vargas-Torres C, Aldy K, Brent J, Wax P, Culbreth R, Krotulski A, Campleman S, Logan B, Abston S, Li S, Manini AF, Fentalog Study Group.   +12 more
europepmc   +1 more source